<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Vet Intern Med</journal-id><journal-id journal-id-type="iso-abbrev">J. Vet. Intern. Med</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1939-1676</journal-id><journal-id journal-id-type="publisher-id">JVIM</journal-id><journal-title-group><journal-title>Journal of Veterinary Internal Medicine</journal-title></journal-title-group><issn pub-type="ppub">0891-6640</issn><issn pub-type="epub">1939-1676</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27282625</article-id><article-id pub-id-type="pmc">5089594</article-id><article-id pub-id-type="doi">10.1111/jvim.14320</article-id><article-id pub-id-type="publisher-id">JVIM14320</article-id><article-categories><subj-group subj-group-type="overline"><subject>Standard Article</subject></subj-group><subj-group subj-group-type="heading"><subject>EQUID</subject><subj-group subj-group-type="heading"><subject>Standard Articles</subject><subj-group subj-group-type="heading"><subject>Respiratory</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Efficacy of Inhaled Levalbuterol Compared to Albuterol in Horses with Recurrent Airway Obstruction</article-title><alt-title alt-title-type="left-running-head">Arroyo et al</alt-title></title-group><contrib-group><contrib id="jvim14320-cr-0001" contrib-type="author"><name><surname>Arroyo</surname><given-names>M.G.</given-names></name><xref ref-type="aff" rid="jvim14320-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jvim14320-cr-0002" contrib-type="author" corresp="yes"><name><surname>Cou&#x000eb;til</surname><given-names>L.L.</given-names></name><xref ref-type="aff" rid="jvim14320-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jvim14320-cr-0003" contrib-type="author"><name><surname>Nogradi</surname><given-names>N.</given-names></name><xref ref-type="aff" rid="jvim14320-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jvim14320-cr-0004" contrib-type="author"><name><surname>Kamarudin</surname><given-names>M.M.</given-names></name><xref ref-type="aff" rid="jvim14320-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jvim14320-cr-0005" contrib-type="author"><name><surname>Ivester</surname><given-names>K.M.</given-names></name><xref ref-type="aff" rid="jvim14320-aff-0001">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="jvim14320-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">Veterinary Clinical Sciences</named-content><institution>Purdue University College of Veterinary Medicine</institution><named-content content-type="city">West Lafayette</named-content><named-content content-type="country-part">IN</named-content></aff><author-notes><corresp id="correspondenceTo"><label>*</label>Corresponding author: L. Cou&#x000eb;til, Purdue University College of Veterinary Medicine, 625 Harrison St, West Lafayette, IN 47906; e&#x02010;mail: <email>couetill@purdue.edu</email>.</corresp></author-notes><pub-date pub-type="epub"><day>09</day><month>6</month><year>2016</year></pub-date><pub-date pub-type="ppub"><season>Jul-Aug</season><year>2016</year></pub-date><volume>30</volume><issue>4</issue><issue-id pub-id-type="doi">10.1111/jvim.2016.30.issue-4</issue-id><fpage>1333</fpage><lpage>1337</lpage><history><date date-type="received"><day>27</day><month>11</month><year>2015</year></date><date date-type="rev-recd"><day>25</day><month>4</month><year>2016</year></date><date date-type="accepted"><day>10</day><month>5</month><year>2016</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2016 American College of Veterinary Internal Medicine <copyright-statement>--><copyright-statement content-type="article-copyright">Copyright &#x000a9; 2016 The Authors. <italic>Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine</italic>.</copyright-statement><license license-type="creativeCommonsBy-nc"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution&#x02010;NonCommercial</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:JVIM-30-1333.pdf"/><abstract id="jvim14320-abs-0001"><sec id="jvim14320-sec-0001"><title>Background</title><p>The (R)&#x02010;enantiomer of racemic albuterol (levalbuterol) has bronchodilatory properties whereas the (S)&#x02010;enantiomer causes adverse effects in human airways, animal models, and isolated equine bronchi. Levalbuterol is commercially available and improves pulmonary function of asthmatic patients with a longer duration of effect than albuterol.</p></sec><sec id="jvim14320-sec-0002"><title>Objective</title><p>To determine the dose at which inhaled levalbuterol produces maximal bronchodilatory effect (<styled-content style="fixed-case">ED</styled-content>max) and determine its duration of action in recurrent airway obstruction (<styled-content style="fixed-case">RAO</styled-content>)&#x02010;affected horses in comparison to racemic albuterol.</p></sec><sec id="jvim14320-sec-0003"><title>Animals</title><p>Nine horses with inducible and reversible <styled-content style="fixed-case">RAO</styled-content>.</p></sec><sec id="jvim14320-sec-0004"><title>Methods</title><p>Randomized, crossover trial. Horses were challenged with moldy hay to induce airway obstruction. Horses were treated with nebulized albuterol or levalbuterol chosen randomly. Pulmonary function testing (<styled-content style="fixed-case">PFT</styled-content>) was measured before and for up to 3 hours after bronchodilatation challenge. Maximum change in transpulmonary pressure (<styled-content style="fixed-case">DP</styled-content>
<sub>max</sub>) was measured to assess the dose effect and duration of action of each drug. After a 24 hours washout period, the bronchodilatation challenge was repeated with the second bronchodilator.</p></sec><sec id="jvim14320-sec-0005"><title>Results</title><p>The duration of effect was 60 minutes for albuterol and 120 minutes for levalbuterol. The dose of bronchodilator <styled-content style="fixed-case">ED</styled-content>max was not significantly different between albuterol and levalbuterol (<styled-content style="fixed-case">ED</styled-content>max = 125.0 [125&#x02013;125 &#x003bc;g] and <styled-content style="fixed-case">ED</styled-content>max = 188 [125&#x02013;188 &#x003bc;g] respectively; <italic>P</italic> = .068). The magnitude of bronchodilatation was not significantly different between the 2 treatments (61.1 and 59.9% decrease in <styled-content style="fixed-case">DP</styled-content>
<sub>max</sub> for albuterol and levalbuterol respectively; <italic>P</italic> = .86).</p></sec><sec id="jvim14320-sec-0006"><title>Conclusions and clinical importance</title><p>Levalbuterol is as effective a bronchodilator as albuterol; although levalbuterol lasts twice as long as albuterol, its duration of action is still too short to make it practical for <styled-content style="fixed-case">RAO</styled-content> treatment.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jvim14320-kwd-0001">Aerosol treatment</kwd><kwd id="jvim14320-kwd-0002">Bronchodilator</kwd><kwd id="jvim14320-kwd-0003">Heaves</kwd></kwd-group><funding-group><award-group><funding-source>Total Wager Tax</funding-source></award-group></funding-group><counts><page-count count="5"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>jvim14320</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>July/August 2016</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.9.6 mode:remove_FC converted:01.11.2016</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="jvim14320-ntgp-0001"><fn id="jvim14320-note-1001"><p>This work was performed at Purdue University.</p></fn></fn-group></notes></front><body><def-list list-content="abbreviations" id="jvim14320-dl-0001"><title>Abbreviations</title><def-item><term><italic>C</italic><sub>dyn</sub></term><def><p>dynamic lung compliance</p></def></def-item><def-item><term>DP<sub>max</sub></term><def><p>maximum change in transpulmonary pressure</p></def></def-item><def-item><term>ED50%</term><def><p>dose producing 50% decrease in DP<sub>max</sub>
</p></def></def-item><def-item><term>ED<sub>max</sub></term><def><p>dose producing maximum bronchodilation</p></def></def-item><def-item><term>IL&#x02010;4</term><def><p>interleukin&#x02010;4</p></def></def-item><def-item><term>IQR</term><def><p>interquartile range</p></def></def-item><def-item><term>PFT</term><def><p>pulmonary function testing</p></def></def-item><def-item><term>RAO</term><def><p>recurrent airway obstruction</p></def></def-item><def-item><term><italic>R</italic><sub><italic>L</italic></sub></term><def><p>lung resistance</p></def></def-item></def-list><p>Recurrent airway obstruction (RAO), also known has &#x0201c;heaves&#x0201d;, is an inducible and reversible chronic inflammatory airway disease commonly encountered in older horses in the northern hemisphere. An episode of acute RAO can be triggered by inhalation of dust from hay and the disease in horses has many similarities to asthma in humans.<xref rid="jvim14320-bib-0001" ref-type="ref">1</xref>, <xref rid="jvim14320-bib-0002" ref-type="ref">2</xref> Functional changes include increases in maximum transpulmonary pressure change (DP<sub>max</sub>) and pulmonary resistance (<italic>R</italic>
<sub><italic>L</italic></sub>) and a decrease in dynamic lung compliance (<italic>C</italic>
<sub>dyn</sub>).<xref rid="jvim14320-bib-0003" ref-type="ref">3</xref>
</p><p>Equine RAO is a disease that cannot be cured but can be managed with medical treatment (systemic or inhaled corticosteroids and bronchodilators) and environmental changes (decreasing dust exposure by modifying housing and diet). Some horses need continuous medical management because of the challenge of achieving appropriate environmental control. Aerosol treatment is considered the best approach because of its rapid onset of action and deposition of high concentration of medication in the peripheral airways while minimizing systemic adverse effects.</p><p>Bronchodilators are used commonly in horses with acute exacerbation of RAO as a rescue medication, as treatment in combination with corticosteroids or as a diagnostic tool.<xref rid="jvim14320-bib-0004" ref-type="ref">4</xref> Albuterol, a short acting &#x003b2;<sub>2</sub>&#x02010;adrenergic receptor agonist, is an effective bronchodilator that relieves acute airway obstruction by relaxing airway smooth muscle.<xref rid="jvim14320-bib-0005" ref-type="ref">5</xref> Within 5 minutes after administration, pulmonary function is improved maximally. The effect, however, lasts only 30&#x02013;60 minutes on average, making long&#x02010;term control of RAO impractical.<xref rid="jvim14320-bib-0004" ref-type="ref">4</xref>, <xref rid="jvim14320-bib-0005" ref-type="ref">5</xref> Albuterol is a racemic mixture containing equal concentrations of (R) &#x02013; and (S)&#x02010;enantiomers. The (R)&#x02010;enantiomer, called levalbuterol, is responsible for the rapid bronchodilatory effect, decrease in wall edema, inhibition of mast cells, and decrease in eosinophilic migration to airways.<xref rid="jvim14320-bib-0006" ref-type="ref">6</xref> The (S)&#x02010;enantiomer has been shown to have adverse effects in the human respiratory tract such as inducing airway hyper&#x02010;responsiveness, increasing production of histamine and interleukin&#x02010;4 (IL&#x02010;4) in mast cells and promoting activation of eosinophils.<xref rid="jvim14320-bib-0006" ref-type="ref">6</xref>, <xref rid="jvim14320-bib-0007" ref-type="ref">7</xref>, <xref rid="jvim14320-bib-0008" ref-type="ref">8</xref> The (S)&#x02010; enantiomer also causes airway hyper&#x02010;responsiveness and bronchoconstriction in isolated equine bronchi in vitro<xref rid="jvim14320-bib-0009" ref-type="ref">9</xref>, but, there is no report regarding the clinical effect of levalbuterol in horses. Levalbuterol is commonly used in human medicine because it improves pulmonary function and provides up to 6 hours of bronchodilatation.<xref rid="jvim14320-bib-0006" ref-type="ref">6</xref>, <xref rid="jvim14320-bib-0010" ref-type="ref">10</xref>, <xref rid="jvim14320-bib-0011" ref-type="ref">11</xref>, <xref rid="jvim14320-bib-0012" ref-type="ref">12</xref> However, recent evidence has shown no clinical benefit of levalbuterol versus albuterol in adult patients with asthma and chronic obstructive pulmonary disease (COPD).<xref rid="jvim14320-bib-0013" ref-type="ref">13</xref> The purpose of our study was to compare the bronchodilatory effect as well as the duration of action of levalbuterol and albuterol in horses with an acute episode of RAO.</p><sec id="jvim14320-sec-0008"><title>Materials and Methods</title><sec id="jvim14320-sec-0009"><title>Study Design</title><p>All methods were approved by the Purdue University Animal Care and Use Committee.</p><p>Nine horses (3 geldings, 6 mares; age range, 9&#x02013;24 years) owned by Purdue University and with a history of inducible and reversible RAO were involved in this randomized, crossover trial. All of the horses remained on pasture on a complete pelleted feed for at least 2 months before the trial to achieve clinical remission. The animals were transported to the research facilities and resided there for the duration of the trial. On arrival, a physical examination and pulmonary function testing (PFT) were performed.</p><p>The horses were housed in individual stalls bedded with wood shavings and fed complete pelleted feed as well as free choice hay placed in a hay net. In addition, they were exposed to moldy hay which was shaken 2 times a day for 3 minutes next to the horse's nose to increase dust exposure.<xref rid="jvim14320-bib-0004" ref-type="ref">4</xref> A daily physical examination was performed, and a clinical score was assigned to every horse based on a scale that ranges from 0 to 21 as previously described.<xref rid="jvim14320-bib-0014" ref-type="ref">14</xref> When the clinical score reached &#x02265;10, PFT was performed. The horse was enrolled in the study if DP<sub>max</sub> &#x02265; 15 cm H<sub>2</sub>O. The PFT was performed at baseline followed by administration of the bronchodilator challenge, randomly chosen (racemic albuterol or levalbuterol). The bronchodilator was given in a stepwise fashion until maximum dilatation was achieved. The PFT was performed 5 minutes after each dose. The horse then was returned to the stall for a washout period of at least 24 hours. The second treatment was administered the next day if the same inclusion criteria were achieved and testing was repeated.</p></sec><sec id="jvim14320-sec-0010"><title>Pulmonary Function Test (PFT)</title><p>An esophageal balloon catheter<xref ref-type="fn" rid="jvim14320-note-1002">1</xref> was placed to obtain measurements analogous to pleural pressure. The position of the catheter was estimated by measuring the distance between the horse's nostrils to mid thorax. The horse was placed in stocks with no sedation and an air&#x02010;tight mask<xref ref-type="fn" rid="jvim14320-note-1003">2</xref> was fitted around the horse&#x02019; muzzle with the port of the mask holding the pneumotachometer<xref ref-type="fn" rid="jvim14320-note-1004">3</xref> to measure airflow. Esophageal pressure and airflow output signals from both devices were recorded simultaneously by computer software<xref ref-type="fn" rid="jvim14320-note-1005">4</xref> for 2 minutes to average the measurement of DP<sub>max</sub> and calculation of pulmonary <italic>R</italic>
<sub><italic>L</italic></sub> and <italic>C</italic>
<sub>dyn</sub> over 10 adequate breaths.<xref rid="jvim14320-bib-0004" ref-type="ref">4</xref>, <xref rid="jvim14320-bib-0015" ref-type="ref">15</xref>
</p></sec><sec id="jvim14320-sec-0011"><title>Bronchodilator Challenge</title><p>A first dose (62.5 &#x003bc;g) of albuterol sulfate<xref ref-type="fn" rid="jvim14320-note-1006">5</xref> or levalbuterol hydrochloride<xref ref-type="fn" rid="jvim14320-note-1007">6</xref> solution was chosen randomly by flipping a coin. This low dose corresponded to 0.15 mL of the bronchodilator solution as measured with a 1&#x02010;mL syringe and given nondiluted. The bronchodilator was administered using an ultrasonic nebulizer<xref ref-type="fn" rid="jvim14320-note-1008">7</xref> and DP<sub>max</sub> measured 5 minutes later. The doses were repeated and the DP<sub>max</sub> was measured 5 minutes after each dose to evaluate the effects of cumulative bronchodilator administration and the dose at which maximal bronchodilatation was achieved. If the DP<sub>max</sub> reached a plateau consisting of a difference &#x02264;10% between 2 successive doses, the air&#x02010;tight mask was repositioned and PFT repeated 10, 20, 30, 40, 60, 90, 120, 180 minutes after the last dose of bronchodilator to determine the duration of the treatment effect, as previously described.<xref rid="jvim14320-bib-0004" ref-type="ref">4</xref> After a washout period of 24 hours, physical examination and clinical scores were obtained to ensure that enrollment criteria were met again, and measurements were repeated after switching treatment drug.</p><p>The dose of bronchodilator that resulted in a 50% decrease in DP<sub>max</sub> (ED50%) was calculated by linear interpolation and the dose resulting in maximum bronchodilatation (ED<sub>max</sub>) was determined as the first dose of the plateau effect.</p></sec><sec id="jvim14320-sec-0012"><title>Statistical Analysis</title><p>Clinical scores and PFT data were compared between treatments using the Wilcoxon Matched Paired Test.<xref ref-type="fn" rid="jvim14320-note-1009">8</xref> The dose that resulted in a 50% and maximum decrease in DP<sub>max</sub> from baseline was compared between both drugs administered. Changes in PFT variables between baseline and subsequent time points were compared using Friedman ANOVA. Post&#x02010;hoc tests were conducted using Wilcoxon matched pairs test when appropriate. Association between DP<sub>max</sub> at baseline and ED<sub>max</sub> was assessed by Spearman's rank correlation. Data were summarized as median and interquartile range (IQR) and significance was defined as <italic>P</italic> &#x0003c; .05.</p></sec></sec><sec id="jvim14320-sec-0013"><title>Results</title><p>All 9 horses met the inclusion criteria and responded to the moldy hay during 2 weeks of exposure. None of them developed anorexia or clinically relevant weight loss throughout the study. Results of baseline PFT (DP<sub>max</sub>, <italic>R</italic>
<sub><italic>L</italic></sub> and <italic>C</italic>
<sub>dyn</sub>) before administration of bronchodilators were not statistically different between the 2 treatment groups (<italic>P</italic> = .76).</p><p>The mean duration of bronchodilator effect was 60 minutes for albuterol and 120 minutes for levalbuterol (Fig <xref rid="jvim14320-fig-0001" ref-type="fig">1</xref>). A comparable response was observed with <italic>R</italic>
<sub><italic>L</italic></sub> data whereby albuterol effect lasted 40 minutes and levalbuterol effect was significant up to 120 minutes (Fig <xref rid="jvim14320-fig-0002" ref-type="fig">2</xref>). Bronchodilator effect on <italic>C</italic>
<sub>dyn</sub> followed a similar trend but was only statistically significant for 10&#x02013;40 minutes. Two of the 9 horses continued to experience decreased DP<sub>max</sub> 3 hours after levalbuterol administration. The effects on PFT were noted after the first dose (63 &#x003bc;g) of either albuterol or levalbuterol and resulted in average decreases of 50 and 56% in DP<sub>max</sub> respectively. The calculated ED50% and ED<sub>max</sub> of the doses were not significantly different between albuterol (ED50% = 43.6 [38.2&#x02013;47.3 &#x003bc;g] and ED<sub>max</sub> = 125.0 [125&#x02013;125 &#x003bc;g]) and levalbuterol (ED50% = 39.7 [35.0&#x02013;52.5 &#x003bc;g; <italic>P</italic> = .40] and ED<sub>max</sub> = 188 [125&#x02013;188 &#x003bc;g; <italic>P</italic> = .068]; Fig <xref rid="jvim14320-fig-0003" ref-type="fig">3</xref>). Similarly, the relative magnitude of bronchodilatation was not significantly different between the 2 treatments (61.1 [43.1&#x02013;67.9] and 59.9 [52.2&#x02013;63.6] % decrease in DP<sub>max</sub> for albuterol and levalbuterol respectively; <italic>P</italic> = .86). There was no significant correlation between DP<sub>max</sub> at baseline and ED<sub>max</sub>.</p><fig fig-type="Figure" xml:lang="en" id="jvim14320-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Mean &#x000b1; standard deviation of the maximum change in transpulmonary pressure (<styled-content style="fixed-case">DP</styled-content>
<sub>max</sub>) recorded with the mask before (0) and after completion of the bronchodilator challenge with albuterol (solid squares) and levalbuterol (open diamonds). *: significantly different from baseline (<italic>P</italic> &#x0003c; .05).</p></caption><graphic id="nlm-graphic-1" xlink:href="JVIM-30-1333-g001"/></fig><fig fig-type="Figure" xml:lang="en" id="jvim14320-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Mean &#x000b1; standard deviation of the lung resistance (<italic>R</italic>
<sub><italic>L</italic></sub>) recorded with the mask before (0) and after completion of the bronchodilator challenge with albuterol (solid squares) and levalbuterol (open diamonds). *: significantly different from baseline (<italic>P</italic> &#x0003c; .05).</p></caption><graphic id="nlm-graphic-3" xlink:href="JVIM-30-1333-g002"/></fig><fig fig-type="Figure" xml:lang="en" id="jvim14320-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Mean &#x000b1; standard deviation of the maximum change in transpulmonary pressure (<styled-content style="fixed-case">DP</styled-content>
<sub>max</sub>) recorded without the mask before (0) and following each dose of nebulized albuterol (solid squares) and levalbuterol (open diamonds). *: significantly different from baseline (<italic>P</italic> &#x0003c; .05).</p></caption><graphic id="nlm-graphic-5" xlink:href="JVIM-30-1333-g003"/></fig></sec><sec id="jvim14320-sec-0014"><title>Discussion</title><p>Levalbuterol, a &#x003b2;&#x02010;agonist containing only the (R)&#x02010;enantiomer of racemic albuterol, has been developed for human asthmatic patients to avoid the adverse effects of the (S)&#x02010;enantiomer.<xref rid="jvim14320-bib-0006" ref-type="ref">6</xref>, <xref rid="jvim14320-bib-0011" ref-type="ref">11</xref>, <xref rid="jvim14320-bib-0012" ref-type="ref">12</xref>, <xref rid="jvim14320-bib-0016" ref-type="ref">16</xref>, <xref rid="jvim14320-bib-0017" ref-type="ref">17</xref> To our knowledge, no previous studies have compared the use of levalbuterol and racemic albuterol for the treatment of horses with an acute episode of RAO.</p><p>Our results suggest that there are no significant differences in the magnitude of improvement in pulmonary function achieved by both bronchodilators, although the effects of levalbuterol lasted twice as long as those of albuterol (2 versus 1 hour respectively). No adverse effects were noted with this single short&#x02010;term treatment with either bronchodilatator, but future studies using daily treatment over several days would be needed to further assess this possibility. Despite this longer duration of action, the return of pulmonary pressures to baseline values by 180 minutes limits the use of levalbuterol to a rescue medication for horses with an acute RAO crisis or as a diagnostic method to confirm reversibility of airway obstruction.</p><p>Before the bronchodilator challenge, there was no significant difference in pulmonary function (DP<sub>max</sub>, <italic>R</italic>
<sub><italic>L</italic></sub>, and <italic>C</italic>
<sub>dyn</sub>) between each arm of the study, demonstrating that a washout period of 24 hours was adequate, as previously reported.<xref rid="jvim14320-bib-0004" ref-type="ref">4</xref>
</p><p>The average albuterol dose that induced a maximum bronchodilatory effect (125 &#x003bc;g) is markedly lower than the dose reported in previous studies (360&#x02013;540 &#x003bc;g).<xref rid="jvim14320-bib-0004" ref-type="ref">4</xref>, <xref rid="jvim14320-bib-0005" ref-type="ref">5</xref> This difference suggests that a higher proportion of drug was deposited in the lung using the ultrasonic nebulizer, presumably because of the smaller particle size delivered with the nebulizer compared to the hand&#x02010;held device used in the previous studies.<xref rid="jvim14320-bib-0004" ref-type="ref">4</xref> The nebulizer was easy to place and it took approximately 1 minute to administer each dose. The horses showed no adverse behavior throughout the bronchodilator challenge, similar to reports in previous studies.<xref rid="jvim14320-bib-0018" ref-type="ref">18</xref> Bronchodilatation was significant after the first dose (63 &#x003bc;g) of either albuterol or levalbuterol, which corresponded to 0.15 mL of solution. We did not attempt to start the bronchodilator challenge with a lower dose because of the difficulty in accurate measurement of small volumes.</p><p>The deposition of the aerosol reaching the lungs in horses with ultrasonic nebulizers (5.09 &#x000b1; 0.66%) is lower than the average 10% of aerosol deposition achieved in human patients.<xref rid="jvim14320-bib-0018" ref-type="ref">18</xref> This difference is likely attributed to horses being nasal breathers, causing higher filtration. In addition, the deposition of small&#x02010;sized aerosol particles in the human lung is augmented by deep inhalation, followed by a period of breath&#x02010;holding at total lung capacity. This maneuver is not possible in horses.<xref rid="jvim14320-bib-0019" ref-type="ref">19</xref>, <xref rid="jvim14320-bib-0020" ref-type="ref">20</xref>, <xref rid="jvim14320-bib-0021" ref-type="ref">21</xref> Horses experiencing an acute RAO episode tend to have rapid and shallow breaths that would be expected to decrease lung deposition of the bronchodilator. However, the doses of albuterol and levalbuterol resulting in ED<sub>max</sub> in horses (125 and 188 &#x003bc;g, respectively) were very small compared to ED<sub>max</sub> reported in human patients with severe asthma exacerbation (7.5 and 3.25 mg respectively).<xref rid="jvim14320-bib-0022" ref-type="ref">22</xref> An additional effect from oral absorption of drugs deposited in the nasopharynx is unlikely because it would be expected to result in a delayed therapeutic effect, but this phenomenon was not observed in our study. Furthermore, there is evidence that oral albuterol is poorly absorbed in the horse<xref ref-type="fn" rid="jvim14320-note-1010">9</xref> and a closely related compound, terbutaline, also is not bioavailable orally in horses.<xref rid="jvim14320-bib-0023" ref-type="ref">23</xref> Therefore, nebulized albuterol and levalbuterol are highly potent bronchodilators in horses with acute RAO exacerbation.</p><p>The effect of levalbuterol lasted 2 hours in RAO horses compared to 6 hours in human asthmatic patients.<xref rid="jvim14320-bib-0012" ref-type="ref">12</xref>, <xref rid="jvim14320-bib-0024" ref-type="ref">24</xref> This decreased duration of action of levalbuterol in the horse is similar to that observed with another bronchodilator, salmeterol xinafoate.<xref rid="jvim14320-bib-0025" ref-type="ref">25</xref> Salmeterol in human asthmatic patients has a duration of action of 12 hours and only 6 hours in horses with RAO. We hypothesized that the difference might be attributed to rapid drug clearance from the lung because of enhanced alveolar and bronchial absorption secondary to increased airway epithelial permeability<xref rid="jvim14320-bib-0025" ref-type="ref">25</xref> or a species&#x02010;specific pharmacokinetic difference in disposition of the drug. There are no validated explanations of why the duration of action of these bronchodilators is shorter in horses than in people.</p><p>Our results suggest that levalbuterol is effective to treat acute RAO in horses but, the only benefit of levalbuterol is the slightly longer duration of bronchodilatory effect compared to albuterol. There was no statistically significant difference in PFT after ED<sub>max</sub> using either bronchodilator. These results suggest that both bronchodilators achieve a similar degree of bronchodilatation in horses, as opposed to humans in whom levalbuterol is more efficient at improving pulmonary function in addition to having a longer acting bronchodilatory effect than albuterol.<xref rid="jvim14320-bib-0006" ref-type="ref">6</xref>
</p><p>In conclusion, unlike findings in human asthmatic patients, administration of levalbuterol to horses with RAO did not result in greater bronchodilatation compared to albuterol. Levalbuterol is an effective bronchodilator, but the short duration of action makes this drug nonpractical for treatment of RAO.</p></sec><sec id="jvim14320-sec-0015"><title>Funding</title><p>The United States Equestrian Federation and the state of Indiana, the Purdue University College of Veterinary Medicine Research account funded by the Total Wager Tax.</p></sec></body><back><ack id="jvim14320-sec-0016"><title>Acknowledgment</title><sec id="jvim14320-sec-0017"><sec id="jvim14320-sec-0018"><p>
<italic>Conflict of Interest Declaration</italic>: Authors declare no conflict of interest.</p><p>
<italic>Off&#x02010;label Antimicrobial Declaration</italic>: Authors declare no off&#x02010;label use of antimicrobials.</p></sec></sec></ack><fn-group id="jvim14320-ntgp-0002"><title>Footnotes</title><fn id="jvim14320-note-1002"><label>1</label><p>Tygon lab catheter, &#x000bc; &#x0201c;ID &#x000d7; 3/8&#x0201d; OD, Cole Parmer, Vernon Hills, IL</p></fn><fn id="jvim14320-note-1003"><label>2</label><p>Equine AeroMask, Trudell Medical International, London, Ontario, Canada</p></fn><fn id="jvim14320-note-1004"><label>3</label><p>No. 4 Fleisch, EMKA Technologies, Paris, France</p></fn><fn id="jvim14320-note-1005"><label>4</label><p>Pulmonary mechanics analyzer, XA version, Buxco Electronics Inc, Sharon, CT</p></fn><fn id="jvim14320-note-1006"><label>5</label><p>1.25 mg of albuterol sulfate in 3&#x02010;mL unit&#x02010;dose vial, Nephron Pharmaceuticals Corporation, Orlando, FL</p></fn><fn id="jvim14320-note-1007"><label>6</label><p>Xopenex<sup>&#x000ae;</sup>, 1.25 mg of levalbuterol in 3&#x02010;mL unit&#x02010;dose vial, Sunovion Pharmaceuticals Inc., Marlborough, MA</p></fn><fn id="jvim14320-note-1008"><label>7</label><p>SaHoMa<sup>&#x02122;</sup> &#x02013; II, NEBU&#x02010;TEC International, Elsenfeld, Germany</p></fn><fn id="jvim14320-note-1009"><label>8</label><p>Statistica, Statsoft Inc., Tulsa, OK</p></fn><fn id="jvim14320-note-1010"><label>9</label><p>Ball MA, Pharmacokinetics of orally administered albuterol in the horse. World Equine Airway Symposium proceedings, 1998</p></fn></fn-group><ref-list content-type="cited-references" id="jvim14320-bibl-0001"><title>References</title><ref id="jvim14320-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jvim14320-cit-0001">
<string-name>
<surname>Ghio</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Mazan</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Hoffman</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Robinson</surname>
<given-names>NE</given-names>
</string-name>. <article-title>Correlates between human lung injury after particle exposure and recurrent airway obstruction in the horse</article-title>. <source>Equine Vet J</source>
<year>2006</year>;<volume>38</volume>:<fpage>362</fpage>&#x02013;<lpage>367</lpage>.<pub-id pub-id-type="pmid">16866207</pub-id></mixed-citation></ref><ref id="jvim14320-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jvim14320-cit-0002">
<string-name>
<surname>Leclere</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lavoie&#x02010;Lamoureux</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lavoie</surname>
<given-names>J&#x02010;P</given-names>
</string-name>. <article-title>Heaves, an asthma&#x02010;like disease of horses</article-title>. <source>Respirology</source>
<year>2011</year>;<volume>16</volume>:<fpage>1027</fpage>&#x02013;<lpage>1046</lpage>.<pub-id pub-id-type="pmid">21824219</pub-id></mixed-citation></ref><ref id="jvim14320-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jvim14320-cit-0003">
<string-name>
<surname>Couetil</surname>
<given-names>LL</given-names>
</string-name>, <string-name>
<surname>Rosenthal</surname>
<given-names>FS</given-names>
</string-name>, <string-name>
<surname>DeNicola</surname>
<given-names>DB</given-names>
</string-name>, <string-name>
<surname>Chilcoat</surname>
<given-names>CD</given-names>
</string-name>. <article-title>Clinical signs, evaluation of bronchoalveolar lavage fluid, and assessment of pulmonary function in horses with inflammatory respiratory disease</article-title>. <source>Am J Vet Res</source>
<year>2001</year>;<volume>62</volume>:<fpage>538</fpage>&#x02013;<lpage>546</lpage>.<pub-id pub-id-type="pmid">11327461</pub-id></mixed-citation></ref><ref id="jvim14320-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jvim14320-cit-0004">
<string-name>
<surname>Bertin</surname>
<given-names>FR</given-names>
</string-name>, <string-name>
<surname>Ivester</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Cou&#x000eb;til</surname>
<given-names>LL</given-names>
</string-name>. <article-title>Comparative efficacy of inhaled albuterol between two hand&#x02010;held delivery devices in horses with recurrent airway obstruction</article-title>. <source>Equine Vet J</source>
<year>2011</year>;<volume>43</volume>:<fpage>393</fpage>&#x02013;<lpage>398</lpage>.<pub-id pub-id-type="pmid">21496081</pub-id></mixed-citation></ref><ref id="jvim14320-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jvim14320-cit-0005">
<string-name>
<surname>Derksen</surname>
<given-names>FJ</given-names>
</string-name>, <string-name>
<surname>Olszewski</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Robinson</surname>
<given-names>NE</given-names>
</string-name>, et al. <article-title>Aerosolized albuterol sulfate used as a bronchodilator in horses with recurrent airway obstruction</article-title>. <source>Am J Vet Res</source>
<year>1999</year>;<volume>60</volume>:<fpage>689</fpage>&#x02013;<lpage>693</lpage>.<pub-id pub-id-type="pmid">10376893</pub-id></mixed-citation></ref><ref id="jvim14320-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jvim14320-cit-0006">
<string-name>
<surname>Nelson</surname>
<given-names>HS</given-names>
</string-name>, <string-name>
<surname>Bensch</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Pleskow</surname>
<given-names>WW</given-names>
</string-name>, et al. <article-title>Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma</article-title>. <source>J Allergy Clin Immunol</source>
<year>1998</year>;<volume>102</volume>:<fpage>943</fpage>&#x02013;<lpage>952</lpage>.<pub-id pub-id-type="pmid">9847435</pub-id></mixed-citation></ref><ref id="jvim14320-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jvim14320-cit-0007">
<string-name>
<surname>Henderson</surname>
<given-names>WR</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>Banerjee</surname>
<given-names>ER</given-names>
</string-name>, <string-name>
<surname>Chi</surname>
<given-names>EY</given-names>
</string-name>. <article-title>Differential effects of (S)&#x02010; and (R)&#x02010;enantiomers of albuterol in a mouse asthma model</article-title>. <source>J Allergy Clin Immunol</source>
<year>2005</year>;<volume>116</volume>:<fpage>332</fpage>&#x02013;<lpage>340</lpage>.<pub-id pub-id-type="pmid">16083788</pub-id></mixed-citation></ref><ref id="jvim14320-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jvim14320-cit-0008">
<string-name>
<surname>Page</surname>
<given-names>CP</given-names>
</string-name>, <string-name>
<surname>Morley</surname>
<given-names>J</given-names>
</string-name>. <article-title>Contrasting properties of albuterol stereoisomers</article-title>. <source>J Allergy Clin Immunol</source>
<year>1999</year>;<volume>104</volume>(<issue>Pt 2</issue>):<fpage>S31</fpage>&#x02013;<lpage>S41</lpage>.<pub-id pub-id-type="pmid">10452786</pub-id></mixed-citation></ref><ref id="jvim14320-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jvim14320-cit-0009">
<string-name>
<surname>Matera</surname>
<given-names>MG</given-names>
</string-name>, <string-name>
<surname>Calzetta</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Rogliani</surname>
<given-names>P</given-names>
</string-name>, et al. <article-title>Evaluation of the effects of the R&#x02010; and S&#x02010;enantiomers of salbutamol on equine isolated bronchi</article-title>. <source>Pulm Pharmacol Ther</source>
<year>2011</year>;<volume>24</volume>:<fpage>221</fpage>&#x02013;<lpage>226</lpage>.<pub-id pub-id-type="pmid">21195788</pub-id></mixed-citation></ref><ref id="jvim14320-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jvim14320-cit-0010">
<string-name>
<surname>Cho</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>Hartleroad</surname>
<given-names>JY</given-names>
</string-name>, <string-name>
<surname>Oh</surname>
<given-names>CK</given-names>
</string-name>. <article-title>(S)&#x02010;albuterol increases the production of histamine and IL&#x02010;4 in mast cells</article-title>. <source>Int Arch Allergy Immunol</source>
<year>2001</year>;<volume>124</volume>:<fpage>478</fpage>&#x02013;<lpage>484</lpage>.<pub-id pub-id-type="pmid">11340331</pub-id></mixed-citation></ref><ref id="jvim14320-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="jvim14320-cit-0011">
<string-name>
<surname>Gupta</surname>
<given-names>MK</given-names>
</string-name>, <string-name>
<surname>Singh</surname>
<given-names>M</given-names>
</string-name>. <article-title>Evidence based review on levosalbutamol</article-title>. <source>Indian J Pediatr</source>
<year>2007</year>;<volume>74</volume>:<fpage>161</fpage>&#x02013;<lpage>167</lpage>.<pub-id pub-id-type="pmid">17337829</pub-id></mixed-citation></ref><ref id="jvim14320-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jvim14320-cit-0012">
<string-name>
<surname>Schreck</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Babin</surname>
<given-names>S</given-names>
</string-name>. <article-title>Comparison of racemic albuterol and levalbuterol in the treatment of acute asthma in the ED</article-title>. <source>Am J Emerg Med</source>
<year>2005</year>;<volume>23</volume>:<fpage>842</fpage>&#x02013;<lpage>847</lpage>.<pub-id pub-id-type="pmid">16291438</pub-id></mixed-citation></ref><ref id="jvim14320-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jvim14320-cit-0013">
<string-name>
<surname>Brunetti</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Poiani</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Dhanaliwala</surname>
<given-names>F</given-names>
</string-name>, et al. <article-title>Clinical outcomes and treatment cost comparison of levalbuterol versus albuterol in hospitalized adults with chronic obstructive pulmonary disease or asthma</article-title>. <source>Am J Health Syst Pharm</source>
<year>2015</year>;<volume>72</volume>:<fpage>1026</fpage>&#x02013;<lpage>1035</lpage>.<pub-id pub-id-type="pmid">26025994</pub-id></mixed-citation></ref><ref id="jvim14320-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jvim14320-cit-0014">
<string-name>
<surname>Tesarowski</surname>
<given-names>DB</given-names>
</string-name>, <string-name>
<surname>Viel</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>McDonell</surname>
<given-names>WN</given-names>
</string-name>. <article-title>Pulmonary function measurements during repeated environmental challenge of horses with recurrent airway obstruction (heaves)</article-title>. <source>Am J Vet Res</source>
<year>1996</year>;<volume>57</volume>:<fpage>1214</fpage>&#x02013;<lpage>1219</lpage>.<pub-id pub-id-type="pmid">8836377</pub-id></mixed-citation></ref><ref id="jvim14320-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="jvim14320-cit-0015">
<string-name>
<surname>Cou&#x000eb;til</surname>
<given-names>LL</given-names>
</string-name>, <string-name>
<surname>Rosenthal</surname>
<given-names>FS</given-names>
</string-name>, <string-name>
<surname>Simpson</surname>
<given-names>CM</given-names>
</string-name>. <article-title>Forced expiration: a test for airflow obstruction in horses</article-title>. <source>J Appl Physiol</source>
<year>2000</year>;<volume>88</volume>:<fpage>1870</fpage>&#x02013;<lpage>1879</lpage>.<pub-id pub-id-type="pmid">10797152</pub-id></mixed-citation></ref><ref id="jvim14320-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="jvim14320-cit-0016">
<string-name>
<surname>Handley</surname>
<given-names>D</given-names>
</string-name>. <article-title>The asthma&#x02010;like pharmacology and toxicology of (S)&#x02010;isomers of beta agonists</article-title>. <source>J Allergy Clin Immunol</source>
<year>1999</year>;<volume>104</volume>(<issue>Pt 2</issue>):<fpage>S69</fpage>&#x02013;<lpage>S76</lpage>.<pub-id pub-id-type="pmid">10452791</pub-id></mixed-citation></ref><ref id="jvim14320-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="jvim14320-cit-0017">
<string-name>
<surname>Perrin&#x02010;Fayolle</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Blum</surname>
<given-names>PS</given-names>
</string-name>, <string-name>
<surname>Morley</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Differential responses of asthmatic airways to enantiomers of albuterol</article-title>. <source>Clin Rev Allergy Immunol</source>
<year>1996</year>;<volume>14</volume>:<fpage>139</fpage>&#x02013;<lpage>147</lpage>.<pub-id pub-id-type="pmid">8866177</pub-id></mixed-citation></ref><ref id="jvim14320-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="jvim14320-cit-0018">
<string-name>
<surname>Votion</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Ghafir</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Munsters</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>Aerosol deposition in equine lungs following ultrasonic nebulisation versus jet aerosol delivery system</article-title>. <source>Equine Vet J</source>
<year>1997</year>;<volume>29</volume>:<fpage>388</fpage>&#x02013;<lpage>393</lpage>.<pub-id pub-id-type="pmid">9306067</pub-id></mixed-citation></ref><ref id="jvim14320-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="jvim14320-cit-0019">
<string-name>
<surname>Chamberlain</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Morgan</surname>
<given-names>WK</given-names>
</string-name>, <string-name>
<surname>Vinitski</surname>
<given-names>S</given-names>
</string-name>. <article-title>Factors influencing the regional deposition of inhaled particles in man</article-title>. <source>Clin Sci (Lond)</source>
<year>1983</year>;<volume>64</volume>:<fpage>69</fpage>&#x02013;<lpage>78</lpage>.<pub-id pub-id-type="pmid">6822051</pub-id></mixed-citation></ref><ref id="jvim14320-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="jvim14320-cit-0020">
<string-name>
<surname>Lippmann</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Yeates</surname>
<given-names>DB</given-names>
</string-name>, <string-name>
<surname>Albert</surname>
<given-names>RE</given-names>
</string-name>. <article-title>Deposition, retention, and clearance of inhaled particles</article-title>. <source>Br J Ind Med</source>
<year>1980</year>;<volume>37</volume>:<fpage>337</fpage>&#x02013;<lpage>362</lpage>.<pub-id pub-id-type="pmid">7004477</pub-id></mixed-citation></ref><ref id="jvim14320-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="jvim14320-cit-0021">
<string-name>
<surname>Newman</surname>
<given-names>SP</given-names>
</string-name>. <article-title>AErosol deposition considerations in inhalation therapy</article-title>. <source>Chest</source>
<year>1985</year>;<volume>88</volume>(<issue>Suppl</issue>):<fpage>152S</fpage>&#x02013;<lpage>160S</lpage>.<pub-id pub-id-type="pmid">3893925</pub-id></mixed-citation></ref><ref id="jvim14320-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="jvim14320-cit-0022">
<string-name>
<surname>Nowak</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Emerman</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Hanrahan</surname>
<given-names>JP</given-names>
</string-name>, et al. <article-title>A comparison of levalbuterol with racemic albuterol in the treatment of acute severe asthma exacerbations in adults</article-title>. <source>Am J Emerg Med</source>
<year>2006</year>;<volume>24</volume>:<fpage>259</fpage>&#x02013;<lpage>267</lpage>.<pub-id pub-id-type="pmid">16635694</pub-id></mixed-citation></ref><ref id="jvim14320-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="jvim14320-cit-0023">
<string-name>
<surname>T&#x000f6;rneke</surname>
<given-names>MK</given-names>
</string-name>, <string-name>
<surname>Ingvast&#x02010;Larsson</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Johansson</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Appelgren</surname>
<given-names>LE</given-names>
</string-name>. <article-title>Pharmacokinetics and pharmacodynamics of terbutaline in healthy horses</article-title>. <source>Am J Vet Res</source>
<year>2000</year>;<volume>61</volume>:<fpage>761</fpage>&#x02013;<lpage>765</lpage>.<pub-id pub-id-type="pmid">10895896</pub-id></mixed-citation></ref><ref id="jvim14320-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="jvim14320-cit-0024">
<string-name>
<surname>Gawchik</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Saccar</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Noonan</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients</article-title>. <source>J Allergy Clin Immunol</source>
<year>1999</year>;<volume>103</volume>:<fpage>615</fpage>&#x02013;<lpage>621</lpage>.<pub-id pub-id-type="pmid">10200010</pub-id></mixed-citation></ref><ref id="jvim14320-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="jvim14320-cit-0025">
<string-name>
<surname>Henrikson</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Rush</surname>
<given-names>BR</given-names>
</string-name>. <article-title>Efficacy of salmeterol xinafoate in horses with recurrent airway obstruction</article-title>. <source>J Am Vet Med Assoc</source>
<year>2001</year>;<volume>218</volume>:<fpage>1961</fpage>&#x02013;<lpage>1965</lpage>.<pub-id pub-id-type="pmid">11417742</pub-id></mixed-citation></ref></ref-list></back></article>